Jun Takeoka1, Tomomi Oka2, Kyoka Fujita1, Satoshi Kurahashi1, Naohiro Toda1,4, Toshiyuki Komiya1,4 and Masaaki Fujita3,5*
1Division of Nephrology, Kansai Electric Power Hospital, Osaka, Japan
2Division of Hematology, Kansai Electric Power Hospital, Osaka, Japan
3Division of Clinical Immunology and Rheumatology, Kansai Electric Power Hospital, Osaka, Japan
4Division of Renal Disease and Blood Purification, Kansai Electric Power Medical Research Institute, Osaka, Japan
5Department of Infectious Diseases, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
*Corresponding author: Masaaki Fujita, Division of Clinical Immunology and Rheumatology, Kansai Electric Power Hospital, Osaka, Japan, 2-1-7 Fukushima, Fukushima-ku, Osaka, 553-0003 Japan. E-mail: fujita.masaaki@e3.kepco.co.jp
Received: October 25, 2021; Accepted: November 02, 2021; Published: November 14, 2021
Citation: Fujita M, Takeoka J, Oka T, et al. Treatment of Secondary Immune Thrombocytopenia with Tacrolimus. Clin Image Case Rep J. 2021; 3(9): 189.
https://www.literaturepublishers.org
Immune thrombocytopenia is an acquired thrombocytopenia caused by antiplatelet autoantibodies. Corticosteroids is used as first-line therapy. In the cases of refractory with corticosteroids, splenectomy, rituximab and thrombopoietin receptor agonists are tried as second-line treatments. However, there are some concerns such as serious infections, thrombosis or bone marrow fibrosis although these treatments have high efficacy rate. We herein described three cases of secondary immune thrombocytopenia with treated with tacrolimus with a brief review of literature. Tacrolimus may have therapeutic potential for secondary immune thrombocytopenia, particularly in patients with low complement levels and/or non-responders to H. pylori eradication therapy.
Keywords: Immune thrombocytopenia; Tacrolimus; Helicobacter pylori; Sjogren’s syndrome; Systemic lupus erythematosus
Comments
Post a Comment